Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus
Kim, Elli A.
Hallett, Travis R.
MetadataShow full item record
CitationLo, Janet, Michael T. Lu, Elli A. Kim, Eric Nou, Travis R. Hallett, Jakob Park, Udo Hoffmann, and Steven K. Grinspoon. 2016. “Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus.” Open Forum Infectious Diseases 3 (2): ofw062. doi:10.1093/ofid/ofw062. http://dx.doi.org/10.1093/ofid/ofw062.
AbstractHepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatosis. This reduction in hepatosteatosis is associated with reduction in low-density lipoprotein cholesterol with statin therapy.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27822361